Literature DB >> 23275140

Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer.

Jian Zhang1, Shao-Hong Huang, Hui Li, Yun Li, Xiu-Ling Chen, Wei-Qing Zhang, Hui-Guo Chen, Li-Jia Gu.   

Abstract

Recently, the prognostic value of cancer-related inflammatory response has been revealed. Previous studies showed that peripheral neutrophils and lymphocytes had significant impact on the prognosis of advanced and early-node-negative non-small-cell lung cancer (NSCLC). The purpose of this study was to investigate the prognostic value of preoperative lymphocyte and neutrophil counts in patients with NSCLC who underwent lobectomy and lymph node dissection and adjuvant chemotherapy. Retrospective analyses were performed to examine the impact of preoperative peripheral lymphocyte and neutrophil counts on disease-free survival (DFS) and overall survival (OS) and to analyze the relationships of these factors to clinicopathological factors. A total of 142 patients with NSCLC were evaluated of which 57 (40.1 %) patients had local recurrence or metastasis. Multivariate analyses revealed that peripheral lymphocyte count was an independent favorable prognostic factor of DFS (hazard ratio 0.548; 95 % confidence interval 0.351-0.857; P = 0.008) but not OS (P = 0.164). The maximum logrank statistical value was 9.504 (P = 0.002) when the cutoff value of lymphocyte was 1,800 mm(-3). The median DFS was 318.0 days (95 % confidence interval 226.0-410.0) for lymphocyte ≤1,800 mm(-3) group and 669.0 days (95 % confidence interval 0.0-1,431.0) for lymphocyte >1,800 mm(-3) group. Low lymphocyte count was related with lymphatic invasion (P = 0.012) and recurrence of NSCLC (P = 0.022). Peripheral neutrophil count had no impact on DFS or OS when analysis included all the 142 patients. Preoperative peripheral lymphocyte count, which is related with lymphatic invasion, is an independent favorable prognostic factor of DFS in patients with NSCLC who underwent lobectomy and lymph node dissection and adjuvant chemotherapy.

Entities:  

Mesh:

Year:  2012        PMID: 23275140     DOI: 10.1007/s12032-012-0352-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  35 in total

1.  Tumor necrosis as a prognostic factor for stage IA non-small cell lung cancer.

Authors:  Seong Yong Park; Hyun-Sung Lee; Hee-Jin Jang; Geon Kook Lee; Kyung Young Chung; Jae Ill Zo
Journal:  Ann Thorac Surg       Date:  2011-06       Impact factor: 4.330

2.  Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer.

Authors:  Naohiro Kobayashi; Shingo Usui; Shinji Kikuchi; Yukinobu Goto; Mitsuaki Sakai; Masataka Onizuka; Yukio Sato
Journal:  Lung Cancer       Date:  2011-07-20       Impact factor: 5.705

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

4.  Survival predictors in advanced non-small cell lung cancer.

Authors:  V Hespanhol; H Queiroga; A Magalhães; A R Santos; M Coelho; A Marques
Journal:  Lung Cancer       Date:  1995-12       Impact factor: 5.705

5.  Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis.

Authors:  M Mori; H Ohtani; Y Naito; M Sagawa; M Sato; S Fujimura; H Nagura
Journal:  Tohoku J Exp Med       Date:  2000-06       Impact factor: 1.848

6.  Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

Authors:  Bernhard Mlecnik; Marie Tosolini; Amos Kirilovsky; Anne Berger; Gabriela Bindea; Tchao Meatchi; Patrick Bruneval; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès; Jérôme Galon
Journal:  J Clin Oncol       Date:  2011-01-18       Impact factor: 44.544

7.  Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.

Authors:  Osamu Kawai; Genichiro Ishii; Kaoru Kubota; Yukinori Murata; Yoichi Naito; Tetsuya Mizuno; Keiju Aokage; Nagahiro Saijo; Yutaka Nishiwaki; Akihiko Gemma; Syoji Kudoh; Atsushi Ochiai
Journal:  Cancer       Date:  2008-09-15       Impact factor: 6.860

8.  Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.

Authors:  Khalid I Al-Shibli; Tom Donnem; Samer Al-Saad; Magnus Persson; Roy M Bremnes; Lill-Tove Busund
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

9.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

10.  Systemic inflammatory response and downmodulation of peripheral CD25+Foxp3+ T-regulatory cells in patients undergoing radiofrequency thermal ablation for lung cancer.

Authors:  Anna Maria Fietta; Monica Morosini; Ileana Passadore; Alessandro Cascina; Paola Draghi; Roberto Dore; Sandro Rossi; Ernesto Pozzi; Federica Meloni
Journal:  Hum Immunol       Date:  2009-03-27       Impact factor: 2.850

View more
  34 in total

1.  Prognostic value of combined platelet, fibrinogen, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with lung adenosquamous cancer.

Authors:  Yu-Qian Wang; Qiong-Jie Zhi; Xin-Yue Wang; Dong-Sheng Yue; Kai Li; Ri-Cheng Jiang
Journal:  Oncol Lett       Date:  2017-07-24       Impact factor: 2.967

2.  Prognostic impact of circulating monocytes and lymphocyte-to-monocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doublet.

Authors:  Gui-Nan Lin; Jie-Wen Peng; Jian-jun Xiao; Dong-Ying Liu; Zhong-Jun Xia
Journal:  Med Oncol       Date:  2014-06-14       Impact factor: 3.064

Review 3.  Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers.

Authors:  Philip A J Crosbie; Rajesh Shah; Yvonne Summers; Caroline Dive; Fiona Blackhall
Journal:  Transl Lung Cancer Res       Date:  2013-10

4.  Prognostic performance of inflammation-based prognostic indices in locally advanced non-small-lung cancer treated with endostar and concurrent chemoradiotherapy.

Authors:  Huarong Tang; Honglian Ma; Fang Peng; Yong Bao; Xiao Hu; Jin Wang; Yujin Xu; Ming Chen
Journal:  Mol Clin Oncol       Date:  2016-03-01

5.  Lymphocyte to monocyte ratio is associated with response to first-line platinum-based chemotherapy and prognosis of early-stage non-small cell lung cancer patients.

Authors:  Ying-Jian Song; Li-Xin Wang; Yong-Qing Hong; Zheng-Hong Lu; Qiang Tong; Xiao-Zheng Fang; Juan Tan
Journal:  Tumour Biol       Date:  2015-11-11

6.  The Prognostic Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Resected Patients with Pancreatic Adenocarcinoma.

Authors:  Le-Ping Fang; Xiao-Yan Xu; Yu Ji; Pu-Wen Huang
Journal:  World J Surg       Date:  2018-11       Impact factor: 3.352

7.  Perioperative change in lymphocyte count and prognosis in esophageal squamous cell carcinoma.

Authors:  Qian Song; Jun-Zhou Wu; Sheng Wang
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

8.  Prognostic and clinicopathological significance of platelet to lymphocyte ratio in esophageal cancer: a meta-analysis.

Authors:  Juhong Deng; Peng Zhang; Yue Sun; Ping Peng; Yu Huang
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

9.  Prognostic significance of systemic inflammation-based lymphocyte- monocyte ratio in patients with lung cancer: based on a large cohort study.

Authors:  Pingping Hu; Hongchang Shen; Guanghui Wang; Ping Zhang; Qi Liu; Jiajun Du
Journal:  PLoS One       Date:  2014-10-02       Impact factor: 3.240

10.  Prognostic significance of platelet-to-lymphocyte ratio in non-small-cell lung cancer: a meta-analysis.

Authors:  Guangliang Qiang; Chaoyang Liang; Fei Xiao; Qiduo Yu; Huanshun Wen; Zhiyi Song; Yanchu Tian; Bin Shi; Yongqing Guo; Deruo Liu
Journal:  Onco Targets Ther       Date:  2016-02-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.